Rectal Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Rectal Cancer – Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rectal Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adlai Nortye Biopharma Co LtdAkeso Inc
AptaBio Therapeutics Inc
Arcus Biosciences Inc
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing StarMab BioMed Technology Ltd
Bio-Thera Solutions Ltd
BioAtla Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
Erasca Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
GSK plc
HCW Biologics Inc
HotSpot Therapeutics Inc
Incyte Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Juntendo University Hospital
Kinnate Biopharma Inc
Kortuc Japan LLC
Kronos Bio Inc
LG Chem Ltd
LIfT BioSciences Ltd
Loxo Oncology Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
Oncolys BioPharma Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pieris Pharmaceuticals Inc
Precigen Inc
Privo Technologies Inc
Pyxis Oncology Inc
Revolution Medicines Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Biosciences Co Ltd
SN BioScience
SQZ Biotechnologies Co
Starpax Biopharma Inc
Sunho (China) Biopharmaceutical Co Ltd
Suzhou Ruotai Pharmaceutical Technology Co Ltd
Taiho Oncology Inc
Takeda Pharmaceutical Co Ltd
Teon Therapeutics Inc
Transcenta Holding Ltd